SELLAS Life Sciences Group, Inc. (SLS)

14.09USD -1.67% (-0.24)

Over 1M: +39.6%

2026-08-25

10 12 14

28 Jul 31 Jul 5 Aug 10 Aug 13 Aug 18 Aug 21 Aug

Figures as at 2023-12-31, reported in USD. The newest fact in the filings is dated 2026-06-30, 57 days ago. Nothing on this page is advice.

How it scores

Five questions, each answered by the measures under it. Every figure is the company's own; the bar beside it is where that figure sits among the companies read here — the top fifth, the bottom fifth, or somewhere between. Not among all listed companies, and for a valuation multiple the low end is the good end.

Durability

How predictable is the revenue, and how much of it is already committed?

1.0

Revenue growth in the worst year on record -100.0%

Cash-flow margin stability 916.3 pp

Resilience

Can the balance sheet absorb a bad year?

10.0

ND/EBITDA 0.051

Current ratio 18.8×

Growth

Is the business getting bigger, and is it getting more profitable?

1.0

Sales/sh Y/Y -100.0%

A measure absent from a block could not be computed from this company's filings. It is left out rather than scored as though it were bad, and the dimension is averaged over what remains. A score is measured against a fixed scale this model states; the bar is measured against the other companies, so the two can disagree — and where they do, that disagreement is the more interesting figure.

Revenue by fiscal year

As the company reported it, one row per year, straight from the filings.

Fiscal year	Ends	Revenue
2012	2012-12-31	0
2013	2013-12-31	2,487,000
2014	2014-12-31	9,319,000
2019	2019-12-31	0
2020	2020-12-31	1,900,000
2021	2021-12-31	7,600,000
2022	2022-12-31	1,000,000
2023	2023-12-31	0

The ratios

The figures themselves rather than their scores — what somebody looking up SLS on one particular measure came for.

Ratio	Value
current ratio	18.83
current ratio reported	18.83
deferred revenue growth	-100.0
growth cv	3.26
revenue growth	-100.0
revenue growth per share	-100.0
rpo growth	0.0

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

Figure	Value	XBRL tag	As at
capex	0	`PaymentsToAcquirePropertyPlantAndEquipment`	2016-12-31
cash	138,343,000	`CashAndCashEquivalentsAtCarryingValue`	2026-06-30
current assets	142,505,000	`AssetsCurrent`	2026-06-30
current liabilities	7,569,000	`LiabilitiesCurrent`	2026-06-30
equity	137,656,000	`StockholdersEquity`	2026-06-30
revenue	0	`RevenueFromContractWithCustomerExcludingAssessedTax`	2023-12-31
sbc	0	`ShareBasedCompensation`	2026-06-30

What to be careful about

operating income last tagged 2026-06-30, -912 days before the revenue period (2023-12-31); dropped rather than divided by current revenue
operating cash flow last tagged 2026-06-30, -912 days before the revenue period (2023-12-31); dropped rather than divided by current revenue
revenue period ends 2023-12-31 (969 days ago) - the tag chain found nothing recent, so treat this row as unscored
no current stock compensation tagged (last tagged 2026-06-30); treated as zero, so owner earnings are overstated
no current capital expenditure tagged (last tagged 2016-12-31); treated as zero, so free cash flow is overstated and equals operating cash flow
no usable diluted share count, so growth is measured on total revenue rather than per share; a company issuing shares to fund that growth reads better than it is

See it scored yourself

The dashboard puts SLS beside other companies and lets you change what counts: the weight of each dimension, the value that earns a ten, and which of the 61 measures are included at all.